Sunshine Biopharma (NASDAQ:SBFM) Posts Earnings Results, Misses Estimates By $1.80 EPS

Sunshine Biopharma (NASDAQ:SBFM) released its earnings results on Thursday. The company reported ($5.20) EPS for the quarter, missing analysts’ consensus estimates of ($3.40) by ($1.80), FiscalAI reports. Sunshine Biopharma had a negative net margin of 17.94% and a negative return on equity of 26.36%. The firm had revenue of $9.44 million during the quarter, compared to analysts’ expectations of $9.60 million.

Sunshine Biopharma Price Performance

NASDAQ:SBFM traded up $0.09 during mid-day trading on Thursday, hitting $2.84. 51,640 shares of the company’s stock were exchanged, compared to its average volume of 115,313. The company has a market cap of $613,440.00, a PE ratio of -0.01 and a beta of 1.32. Sunshine Biopharma has a one year low of $2.53 and a one year high of $464.00. The business has a fifty day moving average price of $10.85 and a 200 day moving average price of $99.61.

Analysts Set New Price Targets

Several brokerages recently weighed in on SBFM. Weiss Ratings raised Sunshine Biopharma from a “sell (e)” rating to a “sell (e+)” rating in a research note on Wednesday, October 28th. Wall Street Zen upgraded Sunshine Biopharma to a “hold” rating in a report on Saturday, October 31st. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Reduce”.

Sunshine Biopharma Company Profile

Sunshine Biopharma, Inc. is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for cancer and other medical conditions. Its lead oncology candidate, Adva-27a, is an investigational small-molecule drug designed to inhibit topoisomerase II, an enzyme involved in cancer-cell replication. The company has studied the compound in preclinical models, including models of breast cancer and multidrug-resistant tumors. In addition to its drug-development activities, Sunshine Biopharma has expanded into the pharmaceutical products business through its Canadian operations.